Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exosomal Markers CD63 and CD9 in Vitiligo Before and After NB-UVB Therapy
Sponsor: Amany El-Agamy Ibrahim El-Samadony
Summary
This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy. Twenty patients with vitiligo were included and received NB-UVB therapy for 3 months. Clinical disease activity and severity were assessed using the Vitiligo Disease Activity (VIDA) score and the Vitiligo Area Severity Index (VASI) before and after treatment. Before treatment, skin biopsies were obtained from lesional and perilesional skin. After treatment, skin biopsies were obtained from repigmented areas. The tissue specimens were evaluated histopathologically and by immunohistochemical staining for CD63 and CD9. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls for comparison.
Official title: Expression of Exosomal Markers (CD63 and CD9) in Lesional Skin of Vitiligo Patients Before and After Narrow-Band Ultraviolet B Therapy: An Immunohistochemical Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-05-20
Completion Date
2026-01-01
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
Narrow-Band Ultraviolet B (NB-UVB) Therapy
Participants with vitiligo received narrow-band ultraviolet B (NB-UVB) phototherapy for 3 months as the study intervention.
Locations (1)
Tanta University Hospitals
Tanta, Gharbia Governorate, Egypt